RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Atrium Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.61−0.06 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $130.18M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$40.28 (−84.11%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $130.18M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.61
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- $12.54
- Diluted shares
- 17M
Two years at a glance
Fiscal years 2024 to 2025, USD
Reported period